An RNA-focused therapeutics company, Seattle-based Shape Therapeutics has developed a technology that is allowing it to evolve programmable RNA medicines that push the limits of current gene editing capabilities in a safer and more effective manner. Chief Scientific Officer David Huss outlined the company’s capabilities in an interview with BioSpace. He said that at its core, Shape has built a number of different platform technologies that span payloads, deliveries and manufacturing. Harnessing the capabilities of machine learning and artificial intelligence programs, Huss said the company strongly relies on information that comes from a patient’s specific mutation and broader, within a disease class. The company’s capabilities allow it to analyze hundreds of billions of therapeutic possibilities and advance breakthroughs in RNA editing, next-generation AAVs and disruptive gene therapy manufacturing.
“We have data in-house that will allow us to predict the sequence of an RNA therapeutic that will allow for an RNA edit for a specific target,” Huss said. “We are inventing new approaches for machine learning and high-throughput screening on a massive scale to engineer completely novel RNAs that correct mutations, fine-tune gene expression and modulate protein interactions.”
